Group 1 - Palvella Therapeutics, Inc. announced the pricing of its upsized public offering of 1,600,000 shares at $125.00 per share, with expected gross proceeds of $200 million [1] - The offering includes a 30-day option for underwriters to purchase an additional 240,000 shares [1] - The offering is expected to close on or about February 27, 2026, subject to customary closing conditions [1] Group 2 - The net proceeds from the offering will be used to support the development of programs including QTORIN rapamycin and QTORIN pitavastatin, as well as for working capital and general corporate purposes [3] - The offering is made pursuant to a shelf registration statement declared effective by the SEC on January 29, 2026 [4] Group 3 - Palvella is focused on developing therapies for serious, rare skin diseases and vascular malformations, with a pipeline based on its patented QTORIN™ platform [6] - The lead product candidate, QTORIN™ rapamycin, is being developed for microcystic lymphatic malformations and other conditions, while QTORIN™ pitavastatin is for the treatment of disseminated superficial actinic porokeratosis [6][7]

Core Viewpoint - Select Water Solutions, Inc. has announced a public offering of $175.0 million of its Class A common stock to support general corporate purposes, including water infrastructure growth, potential acquisitions, and debt repayment [1] Group 1: Offering Details - The public offering is for $175.0 million of Class A common stock, with a par value of $0.01 per share [1] - The company plans to grant underwriters a 30-day option to purchase up to $26.25 million of additional shares at the public offering price [1] - J.P. Morgan Securities LLC and BofA Securities are the lead book-running managers for the offering [1] Group 2: Use of Proceeds - Net proceeds from the offering will be used for general corporate purposes, including water infrastructure growth capital projects, potential acquisitions, or debt repayment under the sustainability-linked credit facility [1] Group 3: Regulatory and Market Conditions - The offering is subject to market and other conditions, with no assurance on the completion or terms of the offering [1] - The offering is being conducted under an effective shelf registration statement filed with the SEC [1]

Core Viewpoint - Genesis Energy, L.P. has successfully priced a public offering of $750 million in senior notes, up from the previously announced $500 million, with a fixed interest rate of 6.75% due in 2034 [1] Group 1: Offering Details - The public offering consists of $750 million in aggregate principal amount of senior notes, which will be co-issued with Genesis Energy Finance Corporation and guaranteed by all subsidiaries except unrestricted ones [1] - The notes will be sold at 100% of their principal amount, and the offering is expected to settle on March 4, 2026, pending customary closing conditions [1] Group 2: Use of Proceeds - The net proceeds from the offering will be used to purchase or redeem all outstanding 7.75% senior notes due 2028 and for general partnership purposes, including repaying a portion of revolving borrowings under the senior secured credit facility [1] Group 3: Market Participation - BofA Securities and Citigroup are acting as joint global coordinators for the offering, with several other financial institutions serving as joint book-running managers [1]

Core Viewpoint - Baltic Horizon Capital AS is offering up to 169,147,497 new units of Baltic Horizon Fund to existing investors, with proceeds aimed at deleveraging the fund's portfolio and enhancing assets [1]. Offering Details - The offering is exclusively for existing investors, with a public offering arranged in Estonia and available to investors in other European Economic Area jurisdictions under specific exemptions [3]. - The offer period starts at 10:00 on 23 February 2026 and ends at 16:00 on 3 March 2026, with the possibility of extension by the company [4]. - The offer price per unit is set at EUR 0.1478, and subscriptions can only be made for whole units [6]. Subscription Process - Existing investors can subscribe for units based on their holdings as of 20 February 2026, multiplied by a coefficient of 1.1782, allowing for a maximum subscription of 1178 units for every 1000 units held [7]. - Investors must hold a securities account in the Estonian Register of Securities and authorize the blocking of the transaction amount until the offering is settled [8]. - A detailed subscription order form is required, specifying the investor's details and the number of units they wish to subscribe for [12]. Key Dates - Key dates for the offering include: - 23 February 2026: Commencement of the offer period - 3 March 2026: End of the offer period - On or about 4 March 2026: Announcement of allocation results - On or about 9 March 2026: Delivery of allocated units and start of trading on Nasdaq Tallinn [11].

Core Viewpoint - Lexicon Pharmaceuticals, Inc. has announced a public offering of 32 million shares at a price of $1.30 per share, aiming to raise approximately $41.6 million before expenses [1] Group 1: Public Offering Details - The public offering consists of 32,000,000 shares priced at $1.30 each, with expected gross proceeds of $41.6 million [1] - The offering is set to close on or about February 2, 2026, pending customary closing conditions [1] - Underwriters have a 30-day option to purchase an additional 4,800,000 shares at the public offering price [1] Group 2: Concurrent Private Placement - Lexicon will also conduct a concurrent private placement, selling 22,400,000 shares of common stock and 184,366 shares of Series B Convertible Preferred Stock for expected gross proceeds of approximately $41.1 million [2] - The Series B Convertible Preferred Stock will convert into 9,218,290 shares of common stock, with an additional option for the purchaser to buy more shares [2] - The private placement is also scheduled to close on or about February 2, 2026, and is not contingent on the public offering [3] Group 3: Use of Proceeds - The net proceeds from both the public offering and private placement will be used to fund ongoing research and development of drug candidates, as well as for working capital and general corporate purposes [4] Group 4: Regulatory Information - A shelf registration statement for the public offering was filed with the SEC and declared effective [5] - The securities offered in the private placement will not be registered under the Securities Act [3]

Core Viewpoint - Lexicon Pharmaceuticals, Inc. has initiated an underwritten public offering of its common stock, with plans to grant underwriters a 30-day option for additional shares, subject to market conditions [1][2] Group 1: Offering Details - The public offering will include shares of common stock with a par value of $0.001, and the actual size and terms of the offering are not guaranteed [1] - Jefferies and Piper Sandler are serving as joint book-running managers for the offering [2] - Concurrently, Lexicon plans to conduct a private placement of common stock to Invus, L.P., its largest stockholder, which will not be registered under the Securities Act [3] Group 2: Use of Proceeds - Lexicon intends to utilize the net proceeds from the offering primarily for the research and development of its drug candidates, as well as for working capital and general corporate purposes [4] Group 3: Regulatory Information - A shelf registration statement related to the offering was filed with the SEC on August 2, 2024, and was declared effective on August 15, 2024 [5]

Group 1 - Greenland Technologies Holding Corporation announced the pricing of its underwritten public offering of 5,083,330 units at a public offering price of $1.20 per unit [1] - Each unit consists of one ordinary share and four-fifths of one warrant, with each whole warrant exercisable for one ordinary share [1][2] - The gross proceeds from the offering are expected to be approximately $6.1 million, intended for working capital and general corporate purposes [2] Group 2 - The offering is expected to close on or about January 29, 2026, subject to customary closing conditions, with Joseph Stone Capital, LLC acting as the sole underwriter [3] - The offering is made pursuant to a registration statement on Form S-1, which was declared effective by the SEC on January 26, 2026 [4] - A final prospectus related to the offering will be filed with the SEC and will be available on the SEC's website [4] Group 3 - Greenland Technologies is a technology developer and manufacturer of electric industrial vehicles and drivetrain systems for material handling machineries and vehicles [6]

Core Viewpoint - ProPetro Holding Corp. has announced an upsized public offering of 15,000,000 shares of common stock at a price of $10.00 per share, increasing from the initially proposed 12,500,000 shares [1] Group 1: Offering Details - The offering consists of 15,000,000 shares priced at $10.00 each, with a 2,500,000 share increase from the original proposal [1] - The net proceeds from the offering will be used for general corporate purposes, including funding growth capital for additional power generation equipment [2] - Underwriters have a 30-day option to purchase an additional 2,250,000 shares at the public offering price [2] Group 2: Management and Closing - Goldman Sachs & Co. LLC is the lead book-running manager for the offering, with Barclays Capital Inc., J.P. Morgan Securities LLC, and BofA Securities as joint book-running managers [3] - The offering is expected to close on January 28, 2026, subject to customary closing conditions [3] Group 3: Company Overview - ProPetro Holding Corp. is based in Midland, Texas, and provides premium completion and power services to leading upstream oil and gas companies involved in the exploration and production of unconventional oil and natural gas resources in North America [6]

Core Viewpoint - ProPetro Holding Corp. has announced a public offering of 12,500,000 shares of its common stock to fund general corporate purposes, including growth capital for additional power generation equipment [1][2]. Group 1: Offering Details - The company intends to use the net proceeds from the offering for general corporate purposes, specifically to fund growth capital for additional power generation equipment [2]. - The offering includes a 30-day option for underwriters to purchase up to an additional 1,875,000 shares at the public offering price, less underwriting discounts and commissions [2]. - Goldman Sachs & Co. LLC is serving as the lead book-running manager for the offering, which is subject to market conditions [3]. Group 2: Regulatory and Legal Information - The offering is being conducted under an effective shelf registration statement filed with the SEC, and a preliminary prospectus supplement has been filed [5]. - The proposed offering will be made only by means of a prospectus and a prospectus supplement, which can be obtained from Goldman Sachs or the SEC's website [4]. Group 3: Company Overview - ProPetro Holding Corp. is based in Midland, Texas, and provides premium completion and power services to leading upstream oil and gas companies involved in the exploration and production of unconventional oil and natural gas resources in North America [6].

Core Viewpoint - National Healthcare Properties, Inc. has confidentially submitted a draft registration statement for a proposed public offering of its common stock, aiming to use the proceeds for debt repayment, property acquisitions, and general corporate purposes [1][2]. Group 1: Offering Details - The number of shares and the price range for the proposed offering have not yet been determined [2]. - The closing of the offering is contingent upon market conditions, SEC review completion, Nasdaq approval, and other customary conditions [2]. Group 2: Company Overview - National Healthcare Properties, Inc. is a publicly registered real estate investment trust focused on acquiring a diversified portfolio of healthcare real estate, particularly in senior housing and outpatient medical facilities in the United States [4].